Exosomes derived from ADSCs suppress the fibrosis process of derma in secondary lymphedema.
Wang X., Li Y., Ye J., Guo X., Xie M., Wang J.
Animal Study, published in Sci Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Sci Rep (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41530227
- PMCID
- PMC12858794
- DOI
- 10.1038/s41598-025-34280-0
Abstract (original English)
Secondary lymphedema (SLE), a progressive condition characterized by limb swelling and tissue fibrosis, frequently arises following oncologic surgery or radiotherapy. Fibrosis in SLE is primarily mediated through the TGFβ-Smad signaling pathway. Adipose derived multipotent mesenchymal stromal cells (ADSCs) and their secreted extracellular vesicles, known as exosomes (ADSC-Exs), have shown therapeutic potential in alleviating SLE. While both ADSCs and ADSC-Exs exhibit anti-fibrotic effects, the extent to which these benefits are attributable to modulation of the TGFβ-Smad pathway remains unclear. EW-7197, a known inhibitor of TGFβ1 signaling, also attenuates fibrosis by suppressing this pathway. However, a direct comparison among ADSCs, ADSC-Exs, and EW-7197 in the context of SLE has not been conducted. This study aims to elucidate the mechanisms by which ADSCs and ADSC-Exs mitigate fibrosis through regulation of the TGFβ-Smad pathway and, for the first time, compares the therapeutic efficacy of ADSCs, ADSC-Exs, and EW-7197 in a model of secondary lymphedema. We established a secondary lymphedema model in C57BL/6 mice through surgical excision and localized radiation. Tissue staining was used to assess fibrosis progression at key time points, identifying the peak fibrosis stage. ADSCs and ADSC-Exs were injected into the affected areas to test their therapeutic effects, while TGF
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.